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There is nometa-analysis of cognitive behavioural therapy for delusions and hallucinations separately. The aimof
this meta-analysis is to evaluate the end-of-treatment effects of individually tailored case-formulation cognitive
behavioural therapy on delusions and auditory hallucinations using symptom-speciﬁc outcome measures.
A systematic search of the trial literature was conducted inMEDLINE, PSYCHINFO and EMBASE. Eighteen studies
were selected with symptom speciﬁc outcome measures. Hedges' g was computed and outcomes were pooled
meta-analytically using the random-effects model.
Our main analyses were with the selected studies with CBT using individually tailored case-formulation that
aimed to reduce hallucinations and delusions. The statistically signiﬁcant effect-sizes were 0.36 with delusions
and 0.44with hallucinations, which are modest and in line with other recentmeta-analyses. Contrasted with ac-
tive treatment, CBT for delusions lost statistical signiﬁcance (0.33), but the effect-size for CBT for hallucinations
increased (0.49). Blinded studies reduced effect-size in delusions (0.24) and gained some in hallucinations
(0.46). There was no heterogeneity in hallucinations andmoderate heterogeneity in delusion trials.We conclude
that CBT is effective in treating auditory hallucinations. CBT for delusions is also effective, but the results must be
interpreted with caution, because of heterogeneity and the non-signiﬁcant effect-sizes when compared with ac-
tive treatment.
© 2014 Elsevier B.V. All rights reserved.
1. Introduction
To date meta-analyses of CBT for psychosis (CBTp) have evaluated
the effects in terms of effects on the frequency and severity of positive
symptoms (Gould et al., 2001; Rector and Beck, 2001; Zimmermann
et al., 2005; Wykes et al., 2008; NICE, 2009), negative symptoms
(Rector and Beck, 2001; Wykes et al., 2008) and general symptoms
(Tarrier and Wykes, 2004; NICE, 2009; Jones et al., 2012), but none fo-
cussed on and differentiated between auditory hallucinations and delu-
sions. CBTp does not aim to reduce the frequency and severity of
symptoms, but rather to reappraise the meaning and purpose of hallu-
cinations and delusions to reduce distress and improve coping in daily
life (Birchwood and Trower, 2006). Therefore, a symptom-speciﬁcmea-
sure may be better suited to measure multiple aspects such as objective
characteristics and subjective experiential aspects of delusions and hal-
lucinations. Recent ﬁndings have shown that formulation based CBTp,
tailored to the individual and carried out by a skilled therapist is the
most efﬁcacious (Steel et al., 2012).
In this reviewwe present the results of ameta-analysis on published
trials that report on the effects of CBTp using individually tailored case-
formulation on hallucinations and/or delusions with the use of a
symptom-speciﬁc measure. We expect that individually tailored case-
formulation CBT will show larger effect-sizes than broad CBT including
standard training programmes.We anticipate larger effect sizes in stud-
ies comparing CBTp with treatment as usual (TAU) to those comparing
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CBTp to an active treatment condition. Furthermore, we expected larger
effect size in studies that were not blinded compared to those, which
were blinded.
2. Methods
2.1. Eligibility criteria
To be included in the review studies had to meet the following
criteria: 1) had to be randomised controlled trials, 2) the experimental
treatmentwas (formulation-based) CBT for psychosis, 3) any control con-
ditionwas accepted, 4) patientswere diagnosedwith a psychotic disorder
with at least 75% schizophrenia patients, 5) were published in peer
reviewed journals, and 6) no conference abstracts, only full papers were
selected. Individually tailored case-formulation CBT was expected to
yield better results in comparison to broadly deﬁned CBT (Steel et al.,
2012). The criteria used to deﬁne individually tailored case-formulation
CBT were quite strict: studies using CBT techniques in a training format
without individually tailored case formulationwere only included in sen-
sitivity analyses. We considered these studies with broad CBT still “ap-
ples”. Studies that were associated with different cognitive techniques,
such as Competitive Memory Training, Acceptance and Commitment
Therapy,Mindfulness training, and Cognitive BiasModiﬁcationwere con-
sidered “oranges” and were not included in the meta-analyses. We limit-
ed the meta-analysis to end-of-treatment data, because too few studies
reported longer-term effects or with varying follow-up periods.
2.2. Information sources
Literature searches were conducted following the PRISMA guideline
(Liberati et al., 2009) using three databases: Ovid MEDLINE and
EMBASE, both from 1996 to July 2013, and PsycINFO from 1987 to July
2013. We also examined published reviews and meta-analyses. The
searchwas conducted at August 3rd 2013.Within each of the databases
three searches were carried out.
2.3. Search
The ﬁrst search was on “CBT” (17385) OR “cognitive therapy”
(54629) OR “cognitive behavioral therapy” (16589) OR “cognitive be-
havioural therapy” (5526).
The second search was on “auditory hallucinations” (4283) OR “au-
ditory verbal hallucinations” (663) OR “AVH” (612) OR “psychosis”
(97486) OR “psychotic symptoms” (16154) OR “delusions” (15394)
OR “paranoia” (7957) OR “paranoid” (15337).
The third search was on “RCT” (20233) OR “randomised controlled
trial” (22216) OR “randomized controlled trial” (610869).
Combining the three searches and the examination of the reviews
resulted in 685 references (see Fig. 1). Removing duplicates left 462 pa-
pers and 4 papers were added from other sources.
2.4. Study selection
All paperswere screened on titles and abstracts. Seventy-two papers
were read and assessed for eligibility. Eighteen papers described
randomised controlled trials of CBT versus a control condition and
used delusions or hallucinations measured separately. One study was
removed because they measured hallucinations with only one item
(England, 2007). One study did not primarily aim for symptom reduc-
tion but relapse prevention (Garety et al., 2008) and was included for
sensitivity analysis. Four studies did not use individually tailored
formulation-based CBT, but were manualised training programmes
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Fig. 1. Flowchart of selected studies.
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aimed at coping behaviour (Cather et al., 2005;Wykes et al., 2005; Penn
et al., 2009) or worry (Foster et al., 2010). These studies were used in
sensitivity analyses too. Excluded studies were not reporting symptom
speciﬁc measures at end-of-treatment (Turkington et al., 2002, 2006);
were not randomised (Morrison et al., 2004); and were not CBTp but
other interventions (Chadwick et al., 2009; Shawyer et al., 2012; van
der Gaag et al., 2012). See Table 2.
2.5. Synthesis of results
The most commonly used symptom-speciﬁc instruments that mea-
sure multiple aspects are the Psychosis Rating Scale (PSYRATS)
(Haddock et al., 1999; Steel et al., 2007), theMacArthur-Maudsley Delu-
sions Assessment Schedule (MADS) (Appelbaum et al., 1999), The Pe-
ters Delusion Inventory (PDI) (Peters et al., 1999), the Comprehensive
Assessment of Psychiatric Symptoms (CPRS) (Asberg et al., 1978) and
the Beliefs about Voices Questionnaire (BaVQ-R) (Chadwick and
Birchwood, 1995; Chadwick et al., 2000).
Some studies reported not full-scale PSYRATS data. The study by
McLeod and colleagues reported three items (McLeod et al., 2007a,b);
the study by Trower and colleagues reported ﬁve items (Trower et al.,
2004). Other studies reported all PSYRATS hallucination items divided
into the three subscales: (a) physical characteristics, (b) emotional
characteristics and (c) cognitive interpretation. Hallucination total
scores were calculated using the formula suggested by Borenstein
et al. (2009). If no PSYRATS scores were available or if only one item
was reported, we choose one of the other symptom-speciﬁc measures
we mentioned above or if absent excluded the study.
Two studies reported all PSYRATS delusions items divided into two
subscales: (a) emotional characteristics and (b) cognitive characteristics.
Sum scores and variance were calculated. The study with the MADS did
not report full-scale results and limited the analysis on an item level
(O'Connor et al., 2007). We have calculated a combined measure on
the items measuring strength of belief, reaction to hypothetical contra-
diction, affect with delusion, preoccupation with delusions and
systematisation of delusion. Most studies report on hallucinations and
delusions, but not all patients in the studies had hallucinations, delu-
sions, or both. As the number of patients (n) we used the proportion of
the patientswith hallucinations or delusions at baseline andwho report-
ed hallucinations or delusions at the end of treatment measurement.
The outcomes across the trials were expressed in Hedges' g (the
standardised mean difference, d, corrected for small sample bias) and
meta-analytically synthesized using ComprehensiveMeta-Analysis ver-
sion 2.2 (www.meta-analysis.com/)with the randomeffectsmodel.We
have chosen end-of-treatment data, because not all studies reported
follow-up data, or used quite variable follow-up periods. For the
meta-analysis, the random effects model was chosen, because hetero-
geneity was expected owing to samples differing across studies and
therapy formats varying from individual to group, and being shorter
or longer.
Heterogeneity is a concern in meta-analysis as it may introduce the
problem of ‘comparing apples with oranges’. Heterogeneity was tested
with a χ2 test. We also report the I2 statistic. When I2 = 0%, 25%, 50%
or 75%, then no, low, moderate or high heterogeneity must be assumed
(Higgins et al., 2003).
Meta-analysis may be subject to publication bias. We conducted
Egger's regression test to quantify the bias captured by the funnel plot
and to test whether it was statistically signiﬁcant (Egger et al., 1997). If
Egger's test was signiﬁcant, then the publication bias was further evalu-
ated using Duval and Tweedie's trim and ﬁll procedure, which yields an
adjusted estimate of the pooled effect-size after the publication bias has
been taken into account (Duval and Tweedie, 2000a, 2000b). Another
way to examine publication bias was to use the fail/safe N analysis,
which indicates the number of missed studies that would render the
pooled effect size to a statistically insigniﬁcant effect (alpha N 0.05).
2.6. Moderator selection
Several moderator analyses explored the data in more detail. Com-
paring with active treatment was expected to yield smaller effect-
sizes than comparing with treatment as usual (TAU) as a control condi-
tion. Blinded studies were expected to reduce the effect-sizes compared
with studies that were not blinded.
2.7. Risk of bias and blind studies
Risk of bias is examined as a dichotomousmoderator and as a contin-
uous measure in a meta-regression analysis. The quality of the studies
was assessed with the Clinical Trials Assessment Measure (CTAM)
(Tarrier and Wykes, 2004; Wykes et al., 2008). This instrument has
been developed to assess the quality of clinical trials of psychosocial in-
terventions and is based on the CONSORT statement. In addition, we di-
chotomized the studies in blinded and not blinded studies formoderator
analysis.
2.8. Sensitivity and moderator analyses
The main analysis comprises trials directed at symptom reduction
with individually tailored case-formulation CBT. Additional sensitivity
analyses were conducted; examining symptom reduction in broad
CBTwith other goals, e.g. worry reduction or coping skills enhancement
and symptom reduction of broad CBT focussed on relapse prevention.
Other moderator analyses were directed at comparing CBT with TAU
or with active treatment, and assessing the effects of blinded trials.
3. Results
3.1. Characteristics of the included studies
Eighteen studies were included in the meta-analyses (Lewis et al.,
2002; Durham et al., 2003; Trower et al., 2004; Cather et al., 2005;
Valmaggia et al., 2005; Wykes et al., 2005; McLeod et al., 2007a,
2007b; O'Connor et al., 2007; Garety et al., 2008; Haddock et al., 2009;
Penn et al., 2009; Foster et al., 2010; Peters et al., 2010; Lincoln et al.,
2012; Krakvik et al., 2013; Leff et al., 2013; Rathod et al., 2013;
Morrison et al., in press). Fifteen studies reported on hallucinations
and twelve on delusions. Of these, two studies had three arms (Lewis
et al., 2002; Durham et al., 2003). We pooled the control conditions in
the overall analyses to prevent double counting of subjects. In the sen-
sitivity analyses for active treatment or TAU, we just selected a single
control condition relevant for that particular analysis. The overall data-
base comprised 1418 patients with auditory hallucinations and/or delu-
sions; 653 had been randomised to the CBT condition and 765 to the
control condition. Table 1 presents a comparison of the studies included
in these twometa-analyses. The number of participants, age and sex are
presented by condition. Table 2 presents the reasons for studies added
in sensitivity analyses and the reasons to exclude studies from analysis
to prevent including apples and oranges.
3.2. Hallucination studies
3.2.1. Overall analysis and sensitivity analyses
Fig. 2 presents the results of all hallucination studies with individu-
ally tailored case-formulation aimed at symptom reduction combined
in a forest plot. Table 3 (upper part) shows the effect-sizes of the overall
meta-analysis in the hallucination trials and two sensitivity analyses
and three moderator analyses. All analyses showed signiﬁcant effect-
sizes ranging from 0.31 to 0.49.
3.2.2. Heterogeneity in the hallucination studies
The Chi-square (Q) was not signiﬁcant in any of the analyses,
pointing to the absence of heterogeneity, as does I2. Therewasmoderate
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Table 1
Description of the interventions, patient characteristics, location, transition criteria, and quality of the studies.
Author Year Format Duration intervention Experimental condition Control condition Country CTAM score Blind rating Selected outcome
measure
CBT format Subjects Age mean (SD) Male sex % Control format Subjects Age mean (SD) Male sex %
Lewis et al. 2002 Indiv 15–20 h in 5 weeks CBT 101 29.1 71% [1] SC
[2] TAU
[1] 106
[2] 102
[1] 27.2
[2] 27.0
[1] 71%
[2] 68%
UK 93 Yes PSYRATS
Durham et al. 2003 Indiv 9 months CBT 22 36.0 (10.0) 68% [1] SC
[2] TAU
[1] 23
[2] 21
[1] 37.0 (11.2)
[2] 36.0 (10.2)
[1] 65%
[2] 71%
UK 79 Yes PSYRATS
Trower et al. 2004 Indiv 6 months CT
CH
18 36.6 (10.3) 56% TAU 20 35.1 (10.4) 70% UK 66 Yes PSYRATS
Wykes et al. 2005 Group 10 weeks CBT 45 39.7 (10.8) 53% TAU 40 39.7 (10.1) 65% UK 56* Yes PSYRATS
Valmaggia et al. 2005 Indiv 6 months CBT 35 35.5 (10.8) 77% SC 23 35.5 (11.4) 61% NL 67 Yes PSYRATS
Cather et al. 2005 Indiv 16 weekly sessions fCBT 16 45.9 (10.2) 25% PE 12 33.1 (10.3) 67% USA 57* No PSYRATS
McLeod et al. 2007 Group 8 weekly sessions CBT 10 n.a. n.a. TAU 10 n.a. n.a. UK 34* No PSYRATS
O'Connor et al. 2007 Indiv 24 weekly sessions CBT 12 40.0 (9.4) 45% APC 12 36.8 (13.5) 67% CAN 49* No MADS
Garety et al. 2008 Indiv 20 sessions in 9 months CBT 60 H
85 D
39.1 (10.3) 71% TAU 60 H 85 D 37.1 (10.9) 72% UK 88 Yes PSYRATS
Penn et al. 2009 Group 12 weeks CBT 32 41.7 (11.8) 53% SC 33 39.6 (15.7) 49% USA 88 Yes PSYRATS
Haddock et al. 2009 Indiv 17 sessions CBT 38 35.7 (12.5) 86% SAT 39 33.9 (9.7) 86% UK 88 Yes PSYRATS
Peters et al. 2010 Indiv 6 months CBT 36 34.0 (9.8) 72% TAU 38 39.6 (10.2) 53% UK 68 No BAVQ
Foster et al. 2010 Indiv 4 sessions Worry-CBT 12 40/0 (10.0) 58% TAU 12 39.1 (9.2) 58% UK 38* No PSYRATS
Lincoln et al. 2012 Indiv 16 weekly sessions CBT 40 33.2 (10.4) 55% TAU 40 33.1 (10.9) 57% GER 82 Yes PDI
Krakvik et al. 2013 Indiv 6 months 20 sessions CBT 23 35.3 (8.9) 65% TAU 22 37.5 (11.2) 64% NO 48* No PSYRATS
Rathod et al. 2013 Indiv 16 weekly sessions Ca CBT 17 31.4 (12.4) 63% TAU 18 35.6 (10.7) 59% UK 58* No CPRS Del. Hall. Scale
Leff et al. 2013 Indiv 6 weekly sessions Avatar CT 14 n.a. n.a. TAU 12 n.a. n.a UK 58* Yes PSYRATS
Morrison et al. 2014 Indiv 9 months CBT 37 33.0 (13.1) 46% TAU 37 29.7 (12.0) 59% UK 81 Yes PSYRATS
CBT = Cognitive behavioural therapy; SC = Supportive counselling/supportive therapy; TAU = Treatment as usual/Waiting list; CTCH = Cognitive Therapy for CommandHallucinations; fCBT = Functional CBT; APC = Attention Placebo Control;
SAT = Social activity treatment; CaCBT = Culturally adapted CBT; UK = United Kingdom; NL = Netherlands; USA = United States of America; CAN = Canada; GER = Germany; NO = Norway; CTAM = Quality rating; * = Risk of bias;
PSYRATS = Psychotic symptom rating scale; MADS = MacArthur-Maudsley Delusions Assessment Schedule; BAVQ = Beliefs about Voices Questionnaire; PDI = Peters Delusion Inventory; CPRS = Comprehensive Psychiatric Rating Scale Delu-
sion and Hallucination Scales.
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heterogeneity in the moderator analysis with active control treatment.
Still, the data must be interpreted with some caution as the number of
trials was quite small and most studies were also underpowered.
3.2.3. Publication bias in the hallucination studies
Egger's regression test did not suggest asymmetry in the funnel plot
of the main and moderator analyses. The effect-sizes did not co-vary
with the blinded ratings. Fail–safe N (alpha = 0.05, 2 sided) shows
that 61 studies with null ﬁndings are necessary to reduce the pooled
effect-size to a non-signiﬁcant one and 36 null ﬁndings to do the same
to blind trials using case-formulation CBT aiming at symptom reduction.
Including broad CBT and relapse reduction studies in the sensitivity
analyses did show publication bias and the Hedges' g was corrected
from 0.31 to 0.27 in broad CBT with other outcomes.
3.3. Delusion studies
3.3.1. Overall analysis and sensitivity analyses
Fig. 3 presents the results of all delusion studies combined in a forest
plot.
Table 3 (lower part) shows the effect-sizes of the overall meta-
analysis in the delusion trials and two sensitivity analyses and three
moderator analyses. The pooled effect is slightly reduced compared
with those in hallucinations, and lost statistical signiﬁcance in contrast
with active treatment.
3.3.2. Heterogeneity in the delusion studies
The Q-statistic was signiﬁcant in almost all analyses, suggesting that
the null-hypothesis of homogeneity had to be rejected. Likewise I2
Table 2
Reasons for including studies in sensitivity analyses or excluding from the analyses.
Study Year
Reason for inclusion in sensitivity analysis
Cather et al. 2005 Not formulation-based CBT: Coping skills based training: “Patients are taught skills for managing persistent positive symptoms that interfere with
accomplishing certain activities or goals; only symptoms that interfere with goal attainment or role functioning are targeted”
Wykes et al. 1999, 2005 Not formulation-basedCBT: Six group sessionswerebased on a cognitive behavioural approach, followed a semi-structured format and lasted for an
hour. Each session dealt with a particular theme: (1) sharing of information about the voices, (2) models of psychosis, (3) models of hallucinations,
(4) effective coping strategies, (5) improving self-esteem, and (6) an overall model of coping with voices.
Penn et al. 2009 Not formulation-based CBT: Coping skills based training: “We modiﬁed the Wykes et al. (1999) manual in the following ways: 1) emphasizing
coping skills rather than cognitive restructuring; 2) deemphasizing self-esteem work; and 3) expanding the protocol from 6–12 sessions so that
more time can be spent on each of the above themes.”
Foster et al. 2010 Not formulation-based CBT, primary outcome worry reduction: “Participants in the W-CBT arm of the trial were offered four sessions over one
month. Theworry reduction strategies includedwere (i) indicated in the literature to be effective at reducing worry, either alone or in conjunction
with other anxiety management strategies; (ii) did not challenge or review the delusion itself; and (iii) had been used by the authors in clinical
practice.”
Garety et al. 2008 Primary outcome relapse prevention: Some CBT, butmost effort on relapse prevention, only 2 items used: “The last stage involved developing a set
of self-regulatory strategies to manage relapse. This would include a pragmatic relapse management plan and the identiﬁcation of particular
behavioural strategies to manage risk situations and early signs as they emerged.”
Reason for exclusion
Turkington et al. 2002, 2006 No hallucination and delusion data at end-of-treatment, just at follow-up
Morrison et al. 2004 Not randomised
England et al. 2007 Reported only one item
Chadwick et al. 2009 No CBT, but Mindfulness meditation and discussion
Van der Gaag et al. 2012 No CBT, but imagery techniques targeted at depression reduction, not hallucinations
Shawyer et al. 2012 No CBT, but Acceptance and Commitment therapy
Study name Statistics for each study Hedges's g and 95% CI
Hedges's Standard Lower Upper 
g error Variance limit limit Z-Value p-Value
Lewis, 2002 0,570 0,241 0,058 0,097 1,043 2,364 0,018
Durham, 2003 0,167 0,269 0,072 -0,360 0,694 0,622 0,534
Trower, 2004 0,654 0,355 0,126 -0,042 1,349 1,842 0,065
Valmaggia, 2005 0,788 0,291 0,085 0,217 1,359 2,704 0,007
McLeod, 2007 0,943 0,454 0,206 0,054 1,832 2,080 0,038
Haddock, 2009 0,111 0,287 0,082 -0,452 0,674 0,387 0,699
Peters, 2010 0,219 0,292 0,085 -0,353 0,791 0,750 0,453
Krakvik, 2013 0,260 0,294 0,087 -0,317 0,836 0,882 0,378
Rathod, 2013 0,154 0,331 0,110 -0,495 0,803 0,465 0,642
Leff, 2013 0,991 0,405 0,164 0,197 1,785 2,447 0,014
Morrison, 2014 0,473 0,233 0,054 0,016 0,931 2,028 0,043
0,435 0,090 0,008 0,260 0,611 4,857 0,000
-2,00 -1,00 0,00 1,00 2,00
Favors Control Favors CBT
Effect of CBT on Hallucinations
Fig. 2. Forest plot of studies using CBT and evaluating the effect on auditory hallucinations.
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points to moderate heterogeneity. Therefore the data must be
interpreted with some caution.
3.3.3. Publication bias in the delusion studies
Egger's regression test showed no publication bias. Fail–safe N indi-
cated that 36 null ﬁndings would be necessary to reduce the observed
effect-size to a non-signiﬁcant one in case-formulation CBT aiming for
symptom reduction.
3.4. Quality of the included studies
The CTAM score (Table 1) describes the methodological quality of
the primary studies. The trialswere rated by two independent senior re-
searchers in psychosis (ABP. S. and S.C.) and minor differences were
discussed and resolved in a consensus meeting. Nine studies were
scored as of poor quality according to CTAM criteria. A meta-
regression analysis of the quality assessment on the effect-size in the
trials found no evidence that higher quality was associated with a
lower effect-size (Delusions: Point estimate of the slope = −0.004;
SE = 0.006; z = −0.562; p = 0.574; Hallucinations: Point estimate
of the slope =−0.004; SE = 0.006; z =−0.641; p = 0.521).
4. Discussion
The results of thismeta-analyses support the general conclusion that
CBTp is effective in treating auditory hallucinations and delusions. The
effect-sizes vary from small to medium and are in line with other
meta-analyses (Pfammatter et al., 2006; Wykes et al., 2008; Jauhar
et al., 2014; Turner et al., in press). There was no statistically signiﬁcant
heterogeneity in the hallucination trials, while moderate heterogeneity
was found in the delusion trials. All trials had improved hallucinations
in the CBTp condition, but two trials reported adverse impacts on delu-
sionswhile the remaining seven trials showed an improvement in delu-
sions in the CBTp condition. Both studies by Durham and colleagues and
Table 3
Random effect-sizes, heterogeneity and publication bias in the main and sensitivity analyses.
Random effect-sizes Heterogeneity Publication bias
Analysis Number of contrasts Hedges' g Z p-value of Z Q (df) p-value of Q I2 Egger's regression
(corrected g)
Fail–safe N
Auditory hallucinations
Main: SR + CF 11 0.44⁎⁎⁎ 4.857 0.000 9.221 (10) 0.511 0/NO 0.225 61
Sensitivity analyses
Broad CBT also training approaches 14 0.35⁎⁎⁎ 4.519 0.000 12.886 (13) 0.457 0/NO 0.130 68
Broad CBT with any primary outcome 15 0.31⁎⁎⁎ 4.114 0.000 15.296 (14) 0.358 0/NO 0.033 (0.27) 69
Moderator analyses
SR + CF compared with TAU 9 0.39⁎⁎⁎ 3.793 0.000 6.330 (8) 0.610 0/NO 0.123 29
SR + CF compared with active treatment 4 0.49⁎ 2.541 0.011 5.072 (3) 0.167 40.9/MOD 0.930 8
SR + CF + blind 8 0.46⁎⁎⁎ 4.482 0.000 7.015 (7) 0.427 0/NO 0.507 36
Delusions
Main: SR + CF 9 0.36⁎ 2.549 0.011 17.993 (8) 0.021 55.5/MOD 0.394 26
Sensitivity analyses
Broad CBT also training approaches 11 0.36⁎⁎ 2.749 0.006 20.786 (10) 0.023 51.9/MOD 0.364 36
Broad CBT with any primary outcome 12 0.31⁎⁎ 2.653 0.008 23.656 (11) 0.014 53.5/MOD 0.149 36
Moderator analyses
SR + CF compared with TAU 6 0.33⁎ 2.015 0.044 10.256 (5) 0.068 51.2/MOD 0.565 8
SR + CF compared with active treatment 5 0.33 1.501 0.133 10.556 (4) 0.032 62.1/MOD 0.915 –
SR + CF + blind 6 0.24⁎ 2.368 0.018 12.603 (5) 0.027 60.3/MOD 0.982 3
SR + CF = Symptom reduction + individually tailored case-formulation; Q = value for heterogeneity tested by Chi-square; I2 = degree of heterogeneity; NO = No heterogeneity;
MOD = Moderate heterogeneity; HIGH = High heterogeneity; – = non-signiﬁcant contrast and no fail–safe N.
⁎ p b .05.
⁎⁎ p b 0.01.
⁎⁎⁎ p b 0.005.
Study name Statistics for each study Hedges's g and 95% CI
Hedges's Standard Lower Upper 
g error Variance limit limit Z-Value p-Value
Lewis, 2002 0,558 0,211 0,045 0,144 0,972 2,641 0,008
Durham, 2003 -0,266 0,269 0,073 -0,794 0,263 -0,985 0,324
Valmaggia, 2005 -0,057 0,265 0,070 -0,576 0,462 -0,216 0,829
O'Connor, 2007 0,594 0,492 0,242 -0,371 1,559 1,206 0,228
Haddock, 2009 0,911 0,305 0,093 0,313 1,509 2,986 0,003
Lincoln, 2012 0,250 0,222 0,049 -0,186 0,686 1,124 0,261
Krakvik, 2013 0,934 0,312 0,098 0,322 1,546 2,990 0,003
Rathod, 2013 0,584 0,364 0,132 -0,130 1,297 1,603 0,109
Morrison 2014 0,044 0,230 0,053 -0,406 0,495 0,193 0,847
0,357 0,140 0,020 0,082 0,631 2,549 0,011
-2,00 -1,00 0,00 1,00 2,00
Favors Control Favors CBT
Effect of CBT on Delusions
Fig. 3. Forest plot of studies using CBT and evaluating the effect on delusions.
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Valmaggia and colleagues speciﬁcally focussed on chronic patients with
medication-resistant patients and had an active treatment in the control
condition (Durham et al., 2003; Valmaggia et al., 2005). These studies
may indicate that delusions are less amenable to change than hallucina-
tions in patients on antipsychotic medication with refractory psychosis.
Individually tailored case-formulation CBT had better results than
broad CBT as expected.
CBTp for delusions compared with active treatment did not attain
statistical signiﬁcance, and had reduced but signiﬁcant effect-size in
blinded studies. CBTp for hallucinations was slightly more effective in
contrast with active treatment and in contrast with blinded studies.
Contrary to our expectation, we did not ﬁnd an effect of the quality
of the trials on the effect-sizes in meta-regression, but blinded versus
not blinded studies were associated with a difference in delusions and
not in hallucinations.
4.1. Strength
The strength of thismeta-analysis is that eighteen trialswere includ-
ed encompassing 1418 patients allowing for relatively detailed evalua-
tion of effects. Nevertheless, more long-term studies are needed to
strengthen the evidence-base and to shed light on the efﬁcacy.
4.2. Limitations
As highlighted above, a limitation is the small number of blind stud-
ies or studies with an active control condition. Ourmeta-analytic results
regarding these sub-sets must be interpreted with some caution.
Another limitation was that it is not certain from the published pa-
pers whether the symptom-speciﬁc measure reported in the results
was chosen at the study design as a primary outcome measure. This
may have resulted in selective outcome reporting where signiﬁcant re-
sults were reported more often than non-signiﬁcant results.
A ﬁnal limitation is our application of the selection criteria for the
primary studies. Our focus on published studies may have introduced
publication bias, but publication bias was not found in the analyses nei-
ther in delusions nor in hallucinations.
4.3. Concluding remarks and recommendations
We join other authors before uswho have advocated the effectiveness
of individual tailored therapy based on case-formulation (Morrison and
Barratt, 2010; Steel et al., 2012). The effect-sizes might increase if more
sensitive outcomemeasures are developed, while more speciﬁc outcome
measuresmay also generatemore informative feedback onwhat types of
CBTp work best for whom and in what clinical outcome dimensions.
The ﬁeld may be also be furthered by the development of more
targeted forms of CBT, for example Trower and colleagues developed
an intervention targeting command hallucinations, which has shown
positive results (Trower et al., 2004). The focus of their intervention
was on modifying the appraisal about the power of the voices, and the
change in appraisal resulted in a decrease of compliance with the com-
mand hallucinations. Also recommended are further studies in the emo-
tional and cognitive processes involved in the development and
maintenance of auditory hallucinations and delusions, which can in-
form the development of tailored CBTp (Garety et al., 2013).
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